What is Anaveon?
Founded in 2017 and headquartered in Switzerland, Anaveon is dedicated to translating complex immunological understanding into tangible therapeutic solutions. The company operates within the biotechnology sector, aiming to address critical unmet medical needs through its innovative pipeline. The recent major strategic investment signals a pivotal moment for Anaveon, likely enabling the acceleration of its clinical development programs and the expansion of its research capabilities.
How much funding has Anaveon raised?
Anaveon has raised a total of $119.5M across 1 funding round:
Series B
$119.5M
Series B (2021): $119.5M with participation from Forbion, Pfizer Ventures, Cowen Healthcare Investments, Pontifax, Syncona, and Novartis Venture Fund
Key Investors in Anaveon
Forbion
Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating the company's philosophy that investments in companies should positively impact the health and well-being of patients.
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages. The company actively scouts disruptive ideas in research centers and builds exceptional companies, providing hands-on guidance and networking to maximize success. They invest in clinical-stage companies, offering strategic direction and expertise in capital markets and mergers & acquisitions. With $1.2 billion managed, Pontifax has established 75 startups and continues to support early-stage and growth-stage ventures.
Syncona
Syncona is a FTSE250 company dedicated to founding, building, and funding healthcare companies that aim to provide transformative treatments for patients facing significant unmet medical needs. The company manages a diversified portfolio of life science firms, including those in various clinical stages, from pre-clinical to late-stage development. Syncona's investment strategy focuses on maximizing shareholder value through key value inflection points, mergers, and liquidity events. Their commitment to sustainability ensures that they support their portfolio companies in making positive contributions to society.
What's next for Anaveon?
With a substantial total funding amount and a recent major strategic investment, Anaveon is well-positioned for its next phase of growth. This capital infusion is expected to fuel the progression of its clinical trials, potentially leading to key milestones in the development of its therapies. The company's focus on immunological insights suggests a strategic direction towards precision medicine and advanced therapeutic modalities. Future developments will likely center on clinical trial outcomes, regulatory advancements, and potential strategic partnerships to bring its life-saving treatments to patients.
See full Anaveon company page
